|
|
Blood, 15 July 2004, Vol. 104, No. 2, pp. 328-335.
Prepublished online as a Blood First Edition Paper on March 25, 2004; DOI 10.1182/blood-2004-01-0002.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories
Marco Herling,
Joseph D. Khoury,
LaBaron T. Washington,
Madeleine Duvic,
Michael J. Keating, and
Dan Jones
From the Departments of Hematopathology, Dermatology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston.
The current World Health Organization (WHO) classification of hematopoietic malignancies defines several types of mature T-cell leukemia including T-cell prolymphocytic leukemia (T-PLL), Sezary syndrome (SS), and T-cell large granular lymphocytic (T-LGL) leukemia. These neoplasms can show overlapping features with each other and with T-cell lymphomas involving peripheral blood (PB). We analyzed the spectrum of clinicopatho-logic features in 102 mature T-cell leukemias and compared them to 10 hepatosplenic T-cell lymphomas that involved PB. T-PLL, defined as a T-cell leukemia showing rapidly rising PB lymphocyte counts, was the only tumor type expressing the oncoprotein TCL1 (71% of cases) and could present with relatively low lymphocyte levels or small tumor cell morphology. SS, defined by accompanying erythrodermic skin disease, was frequently associated with peripheral eosinophilia but could also develop high numbers of prolymphocytes, especially late in the disease course. T-LGL leukemia, defined by accompanying cytopenias or autoimmune phenomena (or both), had the best clinical outcome and generally showed the lowest circulating lymphocyte levels with only a few cases developing marked lymphocytosis. Using the dominant clinical or phenotypic feature, we describe here the degree of overlap among currently recognized WHO categories and identify areas where further clarification is needed. Our results indicate that incorporation of additional criteria, such as TCL1 expression status and hematologic parameters, can assist in a more accurate classification. (Blood. 2004;104:328-335)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
The WHO classification of mature T-cell leukemias
- Daniel Catovsky, Estella Matutes, Claire Dearden, Nnenna Osuji, Vasantha Brito-Babapulle, Marco Herling, and Dan Jones
Blood 2004 104: 2989-2990.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Herling, K. A. Patel, N. Weit, N. Lilienthal, M. Hallek, M. J. Keating, and D. Jones
High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia
Blood,
November 19, 2009;
114(21):
4675 - 4686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi, A. Aribi, S. O'Brien, S. Faderl, D. Jones, A. Ferrajoli, X. Huang, S. York, S. Pierce, W. Wierda, et al.
Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms
J. Clin. Oncol.,
November 10, 2009;
27(32):
5425 - 5430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Martinez-Gallo, C. Puy, R. Ruiz-Hernandez, J. M. Rodriguez-Arias, M. Bofill, J. F. Nomdedeu, J. C. Cigudosa, J. L. Rodriguez-Sanchez, and O. de la Calle-Martin
Severe and recurrent episodes of bronchiolitis obliterans organising pneumonia associated with indolent CD4+ CD8+ T-cell leukaemia
Eur. Respir. J.,
June 1, 2008;
31(6):
1368 - 1372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Herling, K. A. Patel, M. A. Teitell, M. Konopleva, F. Ravandi, R. Kobayashi, and D. Jones
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia
Blood,
January 1, 2008;
111(1):
328 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Despouy, M. Joiner, E. Le Toriellec, R. Weil, and M. H. Stern
The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKC{theta} and ERK pathways
Blood,
December 15, 2007;
110(13):
4406 - 4416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sandberg, K.L. Wu, F. Heule, R.R. van den Bos, K.H. Lam, A.W. Langerak, V.H. van der Velden, K. van Lom, and H.B. Beverloo
Clinically and genetically atypical T-cell prolymphocytic leukemia underlines the relevance of a multidisciplinary diagnostic approach
Haematologica,
March 1, 2007;
92(3):
e34 - e36.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Wlodarski, L. P. Gondek, Z. P. Nearman, M. Plasilova, M. Kalaycio, E. D. Hsi, and J. P. Maciejewski
Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome
Blood,
October 15, 2006;
108(8):
2632 - 2641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Schade, J. J. Powers, M. W. Wlodarski, and J. P. Maciejewski
Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis
Blood,
June 15, 2006;
107(12):
4834 - 4840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Wlodarski, C. O'Keefe, E. C. Howe, A. M. Risitano, A. Rodriguez, I. Warshawsky, T. P. Loughran Jr, and J. P. Maciejewski
Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia
Blood,
October 15, 2005;
106(8):
2769 - 2780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Catovsky, E. Matutes, C. Dearden, N. Osuji, V. Brito-Babapulle, M. Herling, and D. Jones
The WHO classification of mature T-cell leukemias
Blood,
November 1, 2004;
104(9):
2989 - 2990.
[Full Text]
[PDF]
|
|
|
|
|
